Veracyte
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
JP Morgan Healthcare Conference Day 1: Bristol Myers Squibb, Vertex, Sarepta, Novartis, and More
On the first day, companies developing precision medicines and tests discussed plans for diversifying their portfolios and gaining regulatory approval for new products.
Duke Researchers Use Veracyte Data to ID Prostate Cancer Subgroups for Added Post-Surgery Treatment
Premium
The recent JCO Precision Oncology study could bolster the research use case for Veracyte's Decipher GRID database in better defining prostate cancer subgroups.
UnitedHealthcare Issues New Policy Expanding Coverage of Precision Oncology Diagnostics
The private payor added new coverage criteria for sequencing tests in approved companion diagnostic indications, as well as prostate cancer risk assays.
Veracyte to Acquire HalioDx for €260M
Veracyte said the acquisition will help accelerate its in vitro diagnostic test development and manufacturing operations in Europe.